CVS Health Corp (CVS)
$89.79 $0.28 (0.31%) 10:35 PM 11/12/2026
NYSE | $USD | Healthcare PlansStock Data
-
Market Cap
$107.28B -
Day's Range
$88.61 - $90.33 -
Volume
12,978,731 -
52 Week Low / High
$69.51 - $110.68 -
PE Ratio
9.74x -
PEG Ratio
- -
Dividend Frequency
quarterly
Analyst ratings: Buy 25, Hold 2, Sell 0.
Company News
-
CVS Pharmacy® launches latest collection of Caliber® Artist Series colleague-designed journals — Nov 12, 2026
New collection highlights creativity, community and the role of journaling in everyday wellness WOONSOCKET, R.I., Nov. 12, 2026 /PRNewswire/ -- CVS Pharmacy® (NYSE: CVS), the retail division of CVS Health®, today announced the latest collection of journals in its Caliber® Artist Series,...
-
Can CVS Health's 2028 Split Unlock Value Despite Execution Risks? — Nov 12, 2026
CVS Health CVS plans to separate into two publicly traded companies, a move intended to sharpen strategic focus after years of operating an integrated health care model. The transaction is expected to be completed in the first half of 2028. The case for separation rests on faster decisions...
-
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock — Nov 11, 2026
CVS Health (CVS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugstore chain and pharmacy benefits manag...
-
CVS Health CEO doesn't expect end to criticism with split plans — Nov 11, 2026
Heather Diehl/Getty Images News * CVS Health (CVS [https://seekingalpha.com/symbol/CVS]) CEO David Joyner said that he doesn't expect political critiques of his company to end with the planned separation [https://seekingalpha.com/news/4664614-cvs-health-stock-slips-despite-q3-beat] of his ...
-
Top Analyst Reports for NVIDIA, Walmart & AbbVie — Nov 11, 2026
Wednesday, November 11, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pione...
-
Are Medical Stocks Lagging Alector (ALEC) This Year? — Nov 11, 2026
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Alector (ALEC) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we mig...
-
Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist? — Nov 11, 2026
CVS Health CVS is entering a more constructive earnings phase as Aetna margins recover, pharmacy execution improves and cash generation strengthens. Those gains give investors a clearer recovery case after a difficult stretch. The offset is persistent pressure in pharmacy benefit managemen...
-
CVS Health earns global recognition for industry-leading AI and technology innovation — Nov 11, 2026
Seven Stevie® Awards honor innovations across enterprise AI portfolio, including clinical operations, disaster response and workforce development WOONSOCKET, R.I., Nov. 11, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) is being recognized with seven Stevie® Awards for technology and resp...
-
Mark Cuban Calls Out Healthcare Giants Over Hidden Costs, Says Government Would Be 'Negotiating Blind' on Medicare for All — Nov 11, 2026
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Billionaire investor Mark Cuban said Sunday that healthcare giants hide care costs and should be broken up, calling for bipartisan legislation to make every contract public. Blames 'Too Big...
-
What Is CVS Health (CVS) Signaling With Its Faster Biosimilar Push? — Nov 11, 2026
CVS Health (NYSE:CVS) said its CVS Caremark unit is accelerating biosimilar adoption to widen access and manage drug costs. The pharmacy benefit manager is removing Humira from its formularies in favor of lower cost biosimilars for many clients. Caremark is applying a similar approach to S...
Portfolio
Comprised of 1 portfolios


